A Shigella species variant is causally linked to intractable functional constipation

Xin Chen, Tiantian Qiu, Ye Wang, Liyang Xu, Jie Sun, Zhihui Jiang, Wei Zhao, Tao Tao, Yuwei Zhou, Lisha Wei, Yeqiong Li, Yanyan Zheng, Guohua Zhou, Huaqun Chen, Jian Zhang, Xiaobo Feng, Fangyu Wang, Ning Li, Xuena Zhang, Jun Jiang, Min‐Sheng ZhuJournal of Clinical Investigation 2022 · DOI

TL;DR

Researchers have identified a specific strain of Shigella bacteria, dubbed "peristaltic contraction-inhibiting bacterium" (PIB), as a potential cause of intractable functional constipation (IFC). This bacterium produces docosapentenoic acid (DPA), which directly impairs colon motility, and its presence is strongly correlated with IFC in human patients.

What Problem Does This Paper Address?

Intractable functional constipation (IFC) is a severe, debilitating form of constipation that doesn't respond to conventional treatments. Despite its significant impact on patients' quality of life, the underlying causes of IFC have remained largely unknown. This lack of understanding has hindered the development of effective diagnostic and therapeutic strategies. The authors hypothesized that IFC might stem from a persistent, refractory infection by a specific pathogen that disrupts normal colon function.

Methods

The researchers employed a multi-pronged approach:

  • Bacterial Isolation and Screening: They collected colon biopsies from patients with IFC and screened bacterial colonies for their ability to inhibit colonic contraction ex vivo. This led to the identification of "peristaltic contraction-inhibiting bacteria" (PIB).
  • Molecular Identification: 16S rRNA gene sequencing and whole-genome analysis were used to identify the PIB isolate, revealing it to be a novel strain of Shigella.
  • Biochemical Analysis: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to identify docosapentenoic acid (DPA) as the key inhibitory substance produced by PIB.
  • In Vitro and In Vivo Assays:
    • The inhibitory effects of PIB culture supernatants and purified DPA on colonic contraction were tested in isolated colon segments.
  • Mice were orally administered PIB to assess its ability to colonize and induce constipation-like symptoms.
  • A mutated PIB strain with reduced DPA production (PIB-KD) was used to confirm DPA's role in constipation.
  • The efficacy of PIB-specific bacteriophages in clearing PIB and reversing constipation was tested.
  • Diagnostic Development: A specific PCR assay (PIB2013) was developed to detect PIB in fecal samples.
  • Epidemiological Study: Fecal samples from IFC patients, healthy volunteers, and patients with other gastrointestinal conditions were analyzed for the presence of PIB and elevated DPA levels.
  • Histological Analysis: Colon tissues from mice were examined for changes in mucus layer, enteric ganglia, and neurons.

Datasets

  • Human Fecal Samples: Samples were collected from three groups: healthy volunteers (n=97), patients with IFC (n=68), and patients with non-IFC conditions (n=83, including ulcerative colitis and laxative-sensitive constipation).
  • Mouse Models: C57BL/6J mice were used for in vivo colonization and constipation induction studies.
  • Bacterial Strains: A novel Shigella sp. PIB strain was isolated and characterized. Other Shigella and related bacterial strains were used for phylogenetic analysis.

Key Insights and Ideas

  • A Novel Pathogen for IFC: The identification of Shigella sp. PIB as a direct cause of impaired colonic motility is a significant breakthrough in understanding IFC. Previously, the etiology was unknown, making it a "black box" condition.
  • DPA as the Key Mediator: The discovery that DPA, a specific fatty acid produced by PIB, is the direct agent responsible for inhibiting colon contraction is crucial. This provides a specific molecular target for understanding and potentially treating the condition.
  • PIB's Persistent Colonization: The finding that PIB can colonize the mouse gut for extended periods (at least 6 months) explains the "refractory" nature of IFC, suggesting a persistent infection rather than a transient one.
  • Phage Therapy Potential: The successful use of PIB-specific bacteriophages to eliminate PIB and reverse constipation in mice opens a promising avenue for novel therapeutic interventions.
  • Diagnostic Biomarkers: The strong correlation between fecal PIB and elevated DPA levels in IFC patients suggests these can serve as reliable diagnostic markers, moving beyond symptom-based diagnoses.

Key Results

  • PIB Identification: PIB was isolated from 56% (38 of 68) of IFC patients, but not from healthy individuals or non-IFC patients.
  • DPA Elevation: Fecal DPA levels were elevated in 44.1% (30 of 68) of IFC patients, with none of the healthy volunteers showing elevated DPA.
  • DPA Inhibition: DPA significantly inhibited colonic contraction in vitro and induced constipation-like phenotypes in mice.
  • PIB-KD Ineffectiveness: A PIB mutant with reduced DPA production failed to induce constipation in mice, confirming DPA's essential role.
  • Phage Efficacy: Treatment with PIB-specific phages successfully cleared PIB colonization and reversed constipation in mice.
  • Diagnostic Specificity: The developed PIB2013 PCR assay showed high specificity for detecting PIB in fecal samples.

Limitations and Future Work

  • Inconsistency in PIB/DPA Detection: The study noted that some IFC patients were PIB+ but had normal DPA, or vice versa. This inconsistency might be due to the non-uniform distribution of PIB and DPA within stool samples, suggesting the need for optimized sampling and detection methods.
  • Origin of PIB: The exact origin of PIB and how it acquired the ability to produce DPA remains unclear. Future research could investigate whether PIB obtained genes from marine organisms or underwent mutations in its polyketide synthase (PKS) system.
  • Cross-Species Infection Risk: While PIB colonized mice without germ-free conditions, indicating potential for cross-species infection, the risk is considered low due to the generally low levels of PIB in feces. Further surveillance might be warranted.
  • Reclassification of Constipation: The authors suggest that the identification of PIB could lead to a reclassification of constipation, potentially including an "infectious category" based on PIB presence. This would require further validation and clinical studies.
  • Dietary DPA vs. Colon-Produced DPA: While dietary DPA did not affect colon function in mice, DPA applied directly to the colon did. This highlights the importance of localized production within the colon for its pathological effects. Future work could explore the precise mechanisms by which colon-produced DPA exerts its effects, potentially on enteric ganglia.

Summary updated

Abstract

Intractable functional constipation (IFC) is the most severe form of constipation, but its etiology has long been unknown. We hypothesized that IFC is caused by refractory infection by a pathogenic bacterium. Here, we isolated from patients with IFC a Shigella species - peristaltic contraction-inhibiting bacterium (PIB) - that significantly inhibited peristaltic contraction of the colon by production of docosapentenoic acid (DPA). PIB colonized mice for at least 6 months. Oral administration of PIB was sufficient to induce constipation, which was reversed by PIB-specific phages. A mutated PIB with reduced DPA was incapable of inhibiting colonic function and inducing constipation, suggesting that DPA produced by PIB was the key mediator of the genesis of constipation. PIBs were detected in stools of 56% (38 of 68) of the IFC patients, but not in those of non-IFC or healthy individuals (0 of 180). DPA levels in stools were elevated in 44.12% (30 of 68) of the IFC patients but none of the healthy volunteers (0 of 97). Our results suggest that Shigella sp. PIB may be the critical causative pathogen for IFC, and detection of fecal PIB plus DPA may be a reliable method for IFC diagnosis and classification.
BibTeX
@article{chen2022shigella,
  author = {Xin Chen and Tiantian Qiu and Ye Wang and Liyang Xu and Jie Sun and Zhihui Jiang and Wei Zhao and Tao Tao and Yuwei Zhou and Lisha Wei and Yeqiong Li and Yanyan Zheng and Guohua Zhou and Huaqun Chen and Jian Zhang and Xiaobo Feng and Fangyu Wang and Ning Li and Xuena Zhang and Jun Jiang and Min‐Sheng Zhu},
  title = {{A Shigella species variant is causally linked to intractable functional constipation}},
  journal = {Journal of Clinical Investigation},
  year = {2022},
  doi = {10.1172/jci150097},
}
Figure